| Metrics Master Income Trust (MXT) ORDINARY UNITS FULLY PAID |
Financials |
$2,373 |
Proposed issue of securities - MXT
|
29 Aug 2025 8:38AM |
$2.050 |
$1.935 |
fallen by
5.61%
|
|
| PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$2,115 |
PKD Program - Presentation of Safety Data at ANZSN
|
29 Aug 2025 8:37AM |
$1.290 |
$2.150 |
risen by
66.67%
|
|
PYC - Price-sensitive ASX Announcement
Full Release
Key Points
- PYC-003 addresses the root cause of Polycystic Kidney Disease.
- RNA therapy increases expression of the missing PC1 protein.
- Phase 1a/1b trial shows favorable safety and tolerability in healthy volunteers.
- No serious adverse events or renal injury observed.
- Dr. Aron Chakera to present at ANZSN conference.
- Future plans include a Multiple Ascending Dose study and a Phase 1b randomized trial.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$2,115 |
PKD Program - Presentation of Safety Data at ANZSN
|
29 Aug 2025 8:37AM |
$1.290 |
$2.150 |
risen by
66.67%
|
|
PYC - Price-sensitive ASX Announcement
Full Release
Key Points
- PYC-003 is an RNA therapy targeting ADPKD.
- Phase 1 trials show PYC-003 is safe and well-tolerated at doses up to 2.4 mg/kg.
- No serious adverse events or significant changes in kidney markers in healthy volunteers.
- The trial's objective is to establish safety and efficacy in ADPKD patients.
- Studies are conducted across multiple sites in Australia.
- Next phases include evaluating the optimal dosing regimen and assessing efficacy through biomarkers and kidney volume.
- PYC Therapeutics aims for a New Drug Application for PYC-003.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Virgin Australia Holdings Limited (VGN) ORDINARY FULLY PAID |
Industrials |
$2,141 |
FY25 Financial Results ASX Release
|
29 Aug 2025 8:37AM |
$3.490 |
$2.730 |
fallen by
21.78%
|
|
VGN - Price-sensitive ASX Announcement
Full Release
Key Points
- Virgin Australia achieved strong underlying earnings growth in FY25.
- The transformation program delivered over $450 million in benefits.
- Fleet expansion includes new Boeing 737-8 and Embraer E190-E2 aircraft.
- Successful IPO and strengthened partnership with Qatar Airways.
- Velocity loyalty program recorded double-digit revenue growth.
- Continued growth in revenue and profit expected for FY26.
- Comprehensive hedging program in place to manage fuel costs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Virgin Australia Holdings Limited (VGN) ORDINARY FULLY PAID |
Industrials |
$2,141 |
FY25 Financial Results ASX Release
|
29 Aug 2025 8:37AM |
$3.490 |
$2.730 |
fallen by
21.78%
|
|
VGN - Price-sensitive ASX Announcement
Full Release
Key Points
- Pro forma underlying NPAT of $331 million, up 27.8% on FY24.
- Statutory NPAT for FY25 was $479 million, down 12.3% on FY24.
- Virgin Australia's on-time departure rate was 76.8%, up 7.2 percentage points on FY24.
- Completion rate reached 98.4%, up 2.5 percentage points on FY24.
- Transformation Program delivered $450 million in gross benefits.
- Celebrated 25 years of Virgin Australia's operation.
- Strong performance in both Airlines and Velocity segments.
- Strategic partnership strengthened with Qatar Airways Group.
- Continued focus on customer satisfaction and operational excellence.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Memphasys Limited (MEM) ORDINARY FULLY PAID |
Health Care |
$22 |
Preliminary Final Report
|
29 Aug 2025 8:37AM |
$0.004 |
$0.007 |
risen by
75%
|
|
MEM - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing ordinary activities decreased by 94% to $4,000.
- Total income from continuing ordinary activities decreased by 47% to $532,000.
- Net loss for the period attributable to members increased by 11% to $4,942,000.
- Net tangible liabilities per ordinary security remained at (0.2) cents.
- Raised $3,625,100 from the issue of securities.
- Net cash flows used in operating activities were $2,409,785.
- Financial statements are in the process of being audited.
- Total equity decreased to $5,368,114 from $6,837,755.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Memphasys Limited (MEM) ORDINARY FULLY PAID |
Health Care |
$22 |
Preliminary Final Report
|
29 Aug 2025 8:37AM |
$0.004 |
$0.007 |
risen by
75%
|
|
MEM - Price-sensitive ASX Announcement
Full Release
Key Points
- Memphasys Limited is reporting a net loss of $4,941,913 for the financial year ending 30 June 2025.
- Total revenue decreased to $531,980 from $1,273,842 compared to the previous year.
- Significant expenses included employee benefit expenses and research & development expenses.
- Net cash flows from financing activities were $3,146,313.
- Total assets decreased from $12,430,147 to $11,022,086.
- The company issued share capital amounting to $3,730,100.
- Dr. Lindley Edwards appointed as Non-Executive Chairperson in November 2024.
- No significant events occurred post 30 June 2025 that affected the Group's operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Jatcorp Limited (JAT) ORDINARY FULLY PAID |
Consumer Discretionary |
$16 |
FY2025 Financial Report
|
29 Aug 2025 8:37AM |
$0.320 |
$0.140 |
fallen by
56.25%
|
|
| Parkd Ltd (PKD) ORDINARY FULLY PAID |
Industrials |
$5 |
Appendix 4E & Annual Financial Statements 30 June 2025
|
29 Aug 2025 8:36AM |
$0.034 |
$0.032 |
fallen by
5.88%
|
|
PKD - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 218% to $11,830,337.
- Reported a loss of $76,132 for the year, improved from previous year.
- Net assets were $14,576 at the end of the financial year.
- Cash and cash equivalents totaled $674,970 as of 30 June 2025.
- Completion of John Hughes car park and advancement of Audi Centre Myaree projects.
- Strategic goals include expanding product offerings and entering new markets.
- The audit opinion is unmodified but emphasizes material uncertainty regarding going concern.
- The company faces risks such as technology commercialization and construction efficiency.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Parkd Ltd (PKD) ORDINARY FULLY PAID |
Industrials |
$5 |
Appendix 4E & Annual Financial Statements 30 June 2025
|
29 Aug 2025 8:36AM |
$0.034 |
$0.032 |
fallen by
5.88%
|
|
PKD - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from contracts with customers increased significantly to $11,830,337.
- The company reported a loss after income tax of $76,132 for the year.
- Total assets stood at $1,805,852 with liabilities at $1,791,276.
- Net assets at financial year-end were $14,576.
- Issued capital remained constant at $7,227,408.
- Reserves decreased significantly from $512,554 to $242,964.
- Accumulated losses reduced slightly to $7,455,796.
- Key management personnel and directors received share-based payments and remuneration adjustments.
- No dividends were declared for the financial year.
- The audit report declared no contraventions of the Corporations Act 2001 or professional conduct codes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pathkey.AI Ltd (PKY) ORDINARY FULLY PAID |
Information Technology |
$45 |
Preliminary Financial Report - 30 June 2025
|
29 Aug 2025 8:36AM |
$0.022 |
$0.036 |
risen by
63.64%
|
|
PKY - Price-sensitive ASX Announcement
Full Release
Key Points
- Pathkey.AI Ltd changed its name from Opyl Limited.
- The company reported a net loss after income tax of AUD 1,447,743 for the year ending 30 June 2025.
- Revenue from contracts with customers was significantly lower at AUD 27,783 compared to the previous year.
- Government grants and incentives added AUD 292,869 to other income.
- Net cash used in operating activities was AUD 1,284,285.
- Net cash from financing activities amounted to AUD 1,351,163.
- The issued capital increased to AUD 23,640,010.
- The company invested AUD 329,400 in the Digital Bitcoin ETF.
- Pathkey.AI Ltd remained in a net liability position at year-end.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pathkey.AI Ltd (PKY) ORDINARY FULLY PAID |
Information Technology |
$45 |
Preliminary Financial Report - 30 June 2025
|
29 Aug 2025 8:36AM |
$0.022 |
$0.036 |
risen by
63.64%
|
|
PKY - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues decreased by 93.0% to $27,783.
- Loss after tax reduced by 53.8% to $1,447,743.
- No dividends declared or paid during the financial period.
- Net tangible assets per ordinary security stood at -0.11 cents.
- Employee benefits and consultancy costs decreased.
- Significant loss from ordinary activities reflects operational challenges.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Jatcorp Limited (JAT) ORDINARY FULLY PAID |
Consumer Discretionary |
$16 |
Preliminary Final and Full Year Statutory Accounts
|
29 Aug 2025 8:36AM |
$0.320 |
$0.140 |
fallen by
56.25%
|
|
JAT - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant decline in revenue and earnings for FY25.
- Revenue from continuing operations fell by 34% to $34.8 million.
- Group consolidated revenue decreased by 54%.
- Net loss after tax was $6.9 million, down from a profit of $1.6 million in 2024.
- Impairment losses and inventory write-downs impacted financial results.
- Adjusted EBITDA turned negative, indicating operational challenges.
- Market expansion efforts included increased online distribution in China.
- Cash balance at the end of the year was $2.7 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Jatcorp Limited (JAT) ORDINARY FULLY PAID |
Consumer Discretionary |
$16 |
Preliminary Final and Full Year Statutory Accounts
|
29 Aug 2025 8:36AM |
$0.320 |
$0.140 |
fallen by
56.25%
|
|
JAT - Price-sensitive ASX Announcement
Full Release
Key Points
- Jatcorp Limited reported a loss after tax of $2,465,944 for the year ended 30 June 2025, compared to a profit of $2,219,619 the previous year.
- Revenue from continuing operations decreased by 34% to $34,840,126.
- The company did not declare or pay any dividends during the financial year.
- The Group is economically dependent on sales to the People's Republic of China, which constituted 35% of total revenue.
- There was a significant impairment loss of $2,573,115 recognized due to the suspension of sales of Neurio® products in China.
- Jatcorp Ltd's net tangible assets per ordinary security fell from 9.766 cents to 4.672 cents.
- The company consolidated its share capital on a 30-for-one basis during the year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Volt Group Limited (VPR) ORDINARY FULLY PAID |
Utilities |
$18 |
Appendix 4D and Half Yearly Financial Report
|
29 Aug 2025 8:36AM |
$0.115 |
$0.110 |
fallen by
4.35%
|
|
VPR - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues decreased by 24% to $2.15 million.
- Net loss of $271,854 compared to previous year's profit.
- EcoQuip revenue grew by 38%.
- Wescone impacted by order receipt timing.
- Investments in EcoQuip fleet and R&D activities.
- ATEN Concept Study shows carbon reduction benefits.
- 1 for 100 share consolidation on 2 June 2025.
- On-market share buy-back announced.
- Changes in company directorship.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Volt Group Limited (VPR) ORDINARY FULLY PAID |
Utilities |
$18 |
Appendix 4D and Half Yearly Financial Report
|
29 Aug 2025 8:36AM |
$0.115 |
$0.110 |
fallen by
4.35%
|
|
VPR - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased by 24% compared to the previous year.
- EcoQuip business segment observed a 38% growth in revenue.
- Significant investment in EcoQuip Mobile Solar Light Tower fleet and R&D.
- Completed a 1 for 100 share consolidation on 2 June 2025.
- Net operating cash inflow of $267,565.
- Reported loss of $271,854 for the half-year.
- Continued focus on expanding technological and equipment capabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vection Technologies Ltd (VR1) ORDINARY FULLY PAID |
Information Technology |
$57 |
Vection Reports FY25 Results
|
29 Aug 2025 8:35AM |
$0.050 |
$0.024 |
fallen by
52%
|
|
VR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Pro-forma revenue of $42.0 million for FY25.
- Reported revenue increased by 8.7% to $37.5 million.
- First positive underlying EBITDA of $2.8 million.
- Successful integration of The Digital Box acquisition.
- Significant growth driven by Defence sector contracts.
- Expansion in education, healthcare, and industrial sectors.
- Focus on sustainable profitability and global expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vection Technologies Ltd (VR1) ORDINARY FULLY PAID |
Information Technology |
$57 |
Vection Reports FY25 Results
|
29 Aug 2025 8:35AM |
$0.050 |
$0.024 |
fallen by
52%
|
|
VR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Reported revenue increased by 8.7% to AUD 37.5 million.
- First positive EBITDA recorded at AUD 2.8 million.
- Pro-forma revenue of AUD 42.0 million including TDB.
- Significant growth driven by the Defence sector.
- Acquisition of The Digital Box (Algho AI) bolstered AI capabilities.
- Positive operating cash flow demonstrating operational leverage.
- Investments in AI and Spatial Computing are central to strategy.
- Vection's presence expanded in sectors like healthcare and retail.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Visionflex Group Limited (VFX) ORDINARY FULLY PAID |
Health Care |
$4 |
FY25 Results Investor Presentation
|
29 Aug 2025 8:33AM |
$0.003 |
$0.049 |
risen by
1,860%
|
|
VFX - Price-sensitive ASX Announcement
Full Release
Key Points
- Visionflex Group Limited (ASX: VFX) presented its FY25 results on 29 August 2025.
- The company focuses on empowering health practitioners globally with advanced technology for virtual care.
- Visionflex integrates its proprietary software with various third-party medical devices for clinical consultations.
- FY25 saw operating cashflow turn positive at $0.3 million in Q4.
- The company targets growth in aged care, home care, Indigenous health, and resources sectors.
- Visionflex transitioned to a SaaS model, achieving 49% annual recurring revenue (ARR) growth to $1.9 million.
- The company introduced a new software solution for the In-Home Care sector.
- Visionflex expanded its customer base across multiple industry verticals and government-funded customers.
- The balance sheet improved with material reductions in debt and enhanced liquidity.
- Positive outlook for FY26 focusing on SaaS revenue and leveraging strategic partnerships.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Visionflex Group Limited (VFX) ORDINARY FULLY PAID |
Health Care |
$4 |
FY25 Results Investor Presentation
|
29 Aug 2025 8:33AM |
$0.003 |
$0.049 |
risen by
1,860%
|
|
VFX - Price-sensitive ASX Announcement
Full Release
Key Points
- Visionflex transitioned to a SaaS model, increasing ARR by 49% to $1.9 million.
- Gross profit margin improved to 78%.
- Staff costs increased by 39% due to strategic investments.
- Finance costs were reduced by 64%, with further reductions expected.
- Cash balance of $1.9 million supports future growth.
- Secured government-funded contracts and partnerships in key sectors.
- Launched new solutions for the in-home care sector.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Visionflex Group Limited (VFX) ORDINARY FULLY PAID |
Health Care |
$4 |
FY25 Audited Full Year Results
|
29 Aug 2025 8:33AM |
$0.003 |
$0.049 |
risen by
1,860%
|
|
VFX - Price-sensitive ASX Announcement
Full Release
Key Points
- FY25 revenue was $4.7 million, down 33% from previous year.
- Annual Recurring Revenue (ARR) increased by 49% to $1.9 million.
- Gross profit margin improved to 78%.
- Underlying EBITDA loss of $2.5 million, reflecting investments in growth.
- Reduced legacy debt from $6.8 million to $2.4 million.
- Key contracts signed with Amplar Health, BHP, Bupa, and others.
- Launched VisionHome for in-home care market expansion.
- Focus on building a sustainable, profitable organization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Visionflex Group Limited (VFX) ORDINARY FULLY PAID |
Health Care |
$4 |
FY25 Audited Full Year Results
|
29 Aug 2025 8:33AM |
$0.003 |
$0.049 |
risen by
1,860%
|
|
VFX - Price-sensitive ASX Announcement
Full Release
Key Points
- 49% increase in Annual Recurring Revenue (ARR) to $1.9 million.
- FY25 revenue was $4.7 million, down 33% due to previous large hardware contract.
- Recurring software and support revenue grew by 101% to $1.4 million.
- Gross profit margin increased to 78% from recurring software revenue.
- Underlying EBITDA loss of $2.5 million due to lower revenue and strategic investments.
- Legacy debt reduced from $6.8 million to $2.4 million.
- Ended FY25 with $1.9 million in cash.
- Key contracts with Amplar Health, BUPA, and the Royal Flying Doctor Service.
- Focus on market expansion and customer-led innovation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pointsbet Holdings Limited (PBH) ORDINARY FULLY PAID |
Consumer Discretionary |
$308 |
Change in substantial holding
|
29 Aug 2025 8:33AM |
$1.260 |
$0.885 |
fallen by
29.76%
|
|
| Cadence Capital Limited (CDM) ORDINARY FULLY PAID |
Financials |
$233 |
Change of Director's Interest Notice
|
29 Aug 2025 8:33AM |
$0.675 |
$0.780 |
risen by
15.56%
|
|
| Vection Technologies Ltd (VR1) ORDINARY FULLY PAID |
Information Technology |
$57 |
Preliminary Final Report
|
29 Aug 2025 8:33AM |
$0.050 |
$0.024 |
fallen by
52%
|
|
VR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue increased to $36,003,000.
- Loss after income tax was $7,407,000.
- Significant expenses included asset impairments and share-based payments.
- Underlying EBITDA improved to $2,818,000.
- Acquisition of The Digital Box S.p.A. during the period.
- Focus on core operations with INTEGRATEDXR® solutions and services.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
